Patents Examined by Padmavathi Baskar
-
Patent number: 11174308Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.Type: GrantFiled: August 10, 2020Date of Patent: November 16, 2021Assignees: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
-
Patent number: 11173199Abstract: Disclosed are antimicrobial vaccines comprising oligosaccharide ?-(1?6)-glucosamine groups.Type: GrantFiled: March 18, 2020Date of Patent: November 16, 2021Assignee: ALOPEXX INC.Inventors: Michael Wyand, Suman Patel, Gerald F. Swiss
-
Patent number: 11167020Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.Type: GrantFiled: July 24, 2019Date of Patent: November 9, 2021Assignee: Wyeth LLCInventors: George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
-
Patent number: 11167022Abstract: The present invention relates to immunogenic compositions comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.Type: GrantFiled: March 29, 2018Date of Patent: November 9, 2021Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Catherine Cohet, Jeanne-Marie Josephine Devaster, David Mayhew, Bruce Miller, Ruth Tal-Singer, Vincent Weynants, Thomas Wilkinson
-
Patent number: 11167019Abstract: A vaccine platform using a Yersinia pestis mutant synthesizing an adjuvant form lipid A (monophosphoryl lipid A, MPLA) for the increased biogenesis of bacterial outer membrane vesicles (OMVs). To enhance the immunogenicity of the OMVs, an Asd-based balanced-lethal host-vector system was constructed to oversynthesize the LcrV antigen of Y. pestis, raise the amounts of LcrV enclosed in OMVs by Type II secretion system, and eliminate harmful factors like plasminogen activator (Pla) and murine toxin from the OMVs. Vaccination with OMVs containing MPLA and increased amounts of LcrV with diminished toxicity afforded complete protection in mice against subcutaneous challenge and intranasal challenge and was significantly superior to that resulting from vaccination with LcrV/alhydrogel. Additionally, the Yersinia OMV can be used as a platform to deliver the heterologous antigens of Bacillus anthraces.Type: GrantFiled: December 10, 2020Date of Patent: November 9, 2021Assignee: Albany Medical CollegeInventor: Wei Sun
-
Patent number: 11160839Abstract: The disclosure discloses P. pentosaceus CCFM1012, fermented food thereof and application thereof to preparation of a C. jejuni infection antagonism medicine. The P. pentosaceus CCFM1012 of the disclosure can remarkably reduce a colonization rate of in-vivo C. jejuni of mice infected with C. jejuni and transcriptional activity of virulence genes flaA, cadF, cdtB, cdtC and dnaJ of the C. jejuni, can effectively relieve physiological damage caused by infection of the C. jejuni, can also be used for preparing dairy products, bean products and fruit and vegetable fruits for preventing infection of the C. jejuni and an additive that can be added to a poultry and livestock feed for reducing infection and carrying of the C. jejuni in poultry and livestock, and has quite broad application prospects.Type: GrantFiled: September 14, 2020Date of Patent: November 2, 2021Assignee: Jiangnan UniversityInventors: Gang Wang, Wei Chen, Xing Jin, Jianxin Zhao, Hao Zhang
-
Patent number: 11160838Abstract: Methods of treating, removing, or preventing the accumulation of bacteria, fungus, and/or yeast on a surface, and/or treating or preventing fungal, bacterial, and/or yeast infections in a mammal, with compositions containing Bacillus subtilis or material secreted from Bacillus subtilis are provided. Compositions including Bacillus subitlis or material secreted from Bacillus subtilis that can be used in methods of treating, removing, or preventing the accumulation, growth, or activity of bacteria, fungus, and/or yeast on a surface, and/or treating or preventing fungal, bacterial, and/or yeast infections in a mammal, are provided.Type: GrantFiled: August 10, 2020Date of Patent: November 2, 2021Assignee: Deerland Enzymes, Inc.Inventors: John Deaton, Ana Maria Cuentas
-
Patent number: 11149073Abstract: The invention relates to chimeric antigen receptors (CAR) with a humanized targeting domain specific to the antigen ROR1. The invention encompasses the polynucleotides, vectors encoding said CARs and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.Type: GrantFiled: April 27, 2018Date of Patent: October 19, 2021Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Michael Hudecek, Andreas Mades
-
Patent number: 11147864Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of serotypes two of serotypes 1, 3, and 5 are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: February 4, 2019Date of Patent: October 19, 2021Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
-
Patent number: 11142585Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof. In particular, the present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to ERBB2. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.Type: GrantFiled: May 12, 2017Date of Patent: October 12, 2021Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Heng Liang Tan, Andre Boon Hwa Choo
-
Patent number: 11135278Abstract: Provided is a pharmaceutical composition including attenuated Streptococcus pneumoniae strains, and a method thereof for prevention or treatment of inflammatory diseases, respiratory viral infections, bacterial infectious diseases, or allergic diseases.Type: GrantFiled: April 25, 2018Date of Patent: October 5, 2021Assignee: DOKNIP BIOPHARM CO.Inventors: Dong-Kwon Rhee, Seung-Han Seon, Bo-Gyung Kim
-
Patent number: 11129884Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.Type: GrantFiled: January 22, 2020Date of Patent: September 28, 2021Assignee: SOCPRA—SCIENCES ET GENIE, s.e.c.Inventors: Francois Malouin, Marianne Allard, Christian Lebeau Jacob, Brian Geoffrey Talbot, Daniel Scholl, Pierre Lacasse, Moussa S. Diarra, Celine Ster
-
Patent number: 11123417Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: February 4, 2019Date of Patent: September 21, 2021Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
-
Patent number: 11122814Abstract: The present invention discloses beverage compositions comprising probiotic Bacillus coagulans and water soluble prebiotic fibers that have been subjected to treatments under extreme stress, temperature and pressure conditions like brewing or aeration wherein the spore viability is maintained post said treatments.Type: GrantFiled: February 26, 2020Date of Patent: September 21, 2021Assignee: SAMI LABS LIMITEDInventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali, Shaheen Majeed
-
Patent number: 11116830Abstract: Immunogenic compositions that include a bacterial capsular polysaccharide conjugated to a carrier protein are described. In some embodiments, the bacterial capsular polysaccharide is a Neisseria meningitidis capsular polysaccharide. The carrier protein includes an N. meningitidis factor H binding protein (fHbp) linked to cholera toxin subunit B (CTB). Administration of the immunogenic compositions elicits an immune response that includes production of meningococcal polysaccharide-specific and fHbp-specific antibodies. Use of the immunogenic compositions as meningococcal vaccines is also described.Type: GrantFiled: December 18, 2018Date of Patent: September 14, 2021Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Gregory A. Price, Che-Hung Robert Lee, Margaret C. Bash
-
Patent number: 11104892Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.Type: GrantFiled: May 27, 2020Date of Patent: August 31, 2021Assignees: President and Fellows of Harvard College, Massachusetts Institute of TechnologyInventors: R. John Collier, Isaac Chiu, Bradley L. Pentelute
-
Patent number: 11103569Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against an infection with Streptococcus suis of serotype 2 and against an infection with Streptococcus suis of serotype 9.Type: GrantFiled: December 14, 2018Date of Patent: August 31, 2021Assignee: Intervet Inc.Inventor: Antonius Arnoldus Christiaan Jacobs
-
Patent number: 11103564Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH)enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.Type: GrantFiled: June 19, 2019Date of Patent: August 31, 2021Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, MUSEUM NATIONAL D'HISTOIRE NATURELLE, ECOLE NATIONALE VETERINAIRE D'ALFORTInventors: Luis G. Bermudez-Humaran, Thibault Allain, Isabelle Florent, Philippe Langella, Philippe Grellier, Marie-Agnes Travers, Bruno Polack
-
Patent number: 11098122Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.Type: GrantFiled: December 19, 2018Date of Patent: August 24, 2021Assignee: HARBOUR BIOMED (SHANGHAI) CO., LTD.Inventors: Xin Gan, Yun He, Yuqiang Shen, Jiuqiao Zhao, Yiping Rong, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens
-
Patent number: 11078258Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.Type: GrantFiled: April 28, 2020Date of Patent: August 3, 2021Assignee: NEW YORK UNIVERSITYInventors: Victor J. Torres, Francis Alonzo, III